Prodia Diagnostic Line Tbk vs Kian Santang Muliatama Tbk. — how do they compare? Prodia Diagnostic Line Tbk trades at Rp236 (market cap 428.75B, 13.83M 24h volume), while Kian Santang Muliatama Tbk. trades at Rp114 (market cap 163.43B, 36.43M 24h volume). The key difference: Prodia Diagnostic Line Tbk is far larger — about 2.6× Kian Santang Muliatama Tbk.'s market cap, and Kian Santang Muliatama Tbk. is more actively traded (36.43M versus 13.83M). Which is the better fit depends on your goals.
| PRDL | RGAS | |
|---|---|---|
Market Cap | 428.75B | 163.43B |
Volume | 13.83M | 36.43M |
Lot | 138.27K | 364.26K |
Turnover | 3.27B | 4B |
Average Price | 236.62 | 109.89 |
Value | 3.27B | 4B |
Indicative Equilibrium Price | 236 | 114 |
Indicative Equilibrium Volume | 1.74K | 5.9K |
Trailing returns across standard periods
Latest headlines on both assets
PT Prodia Diagnostic Line Tbk (the Company) was established April 16, 2010 with the name of PT DiaLine Systems Indonesia based on Notarial Deed No. 22 of Rismalena Kasri, S.H. On April 25, 2011, PT DiaLine Systems Indonesia changed the Companys name to PT Prodia Diagnostic Line based on Notarial Deed No. 14 of Rismalena Kasri, S.H. The Company is in the form of a Limited Liability Company in 2010 and began commercial production in 2011. The production results are marketed locally. The parent and ultimate parent entity of the Company is PT Prodia Utama.
Read more on PRDL →PT Kian Santang Muliatama Tbk (the Entity) was established based on the Notarial Deed of Artisa Khamelia Ramadiyanti, S.H., M.Kn., No. 634, dated November 28, 2018. The Entity started its commercial operations on 2019. The controlling party for the Company is Edy Nurhamid Amin.
Read more on RGAS →